Apimeds Pharmaceuticals US Long Term Debt

The latest long-term debt for APUS is $120K as of March 2026. That compares with $250K in the prior-year period — down 52.5% year over year. Investors often review this figure alongside Apimeds Pharmaceuticals US's historical trend and sector peers before judging valuation or financial health.

Over the past year, APUS's long-term debt moved from $250K to $120K — a 52.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Apimeds Pharmaceuticals US's operating scale or balance-sheet position.

A long-term debt figure of $120K for APUS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting APUS's long-term debt ($120K), review year-over-year change from $250K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.